Bookmark Email Print this page

Life sciences

Shifting demographics. Shrinking margins. Evolving regulations. Rising R&D costs. There is little doubt that life sciences companies face a range of significant challenges for the years ahead. To adapt effectively, pharmaceutical, medical devices and biotechnology organizations must not only accelerate their development processes, they must also re-examine their underlying operational strategies.

Deloitte’s professionals have experience working with life sciences companies across the country to enhance revenues, manage costs and improve asset turnover. Our industry specialists can help you refine your business models through innovative partnerships, improved processes and more effective compliance — ultimately strengthening both patient care and stakeholder value.

 Canada’s biopharmaceutical companies compete  Helping Canada’s biopharmaceutical companies compete
"Take the lead" explores the challenges facing the biopharmaceutical industry and identifies global best practices Canadian organizations can adopt to enhance their competitive positioning.

Related links

  • 2011 Canadian consumer health survey
    View archive
  • Convergence in the Life Sciences industry
    A Deloitte Research report

Featured content

  • ExternalURL Life sciences in Alberta: State of the industry 2011
    The BioAlberta State report reviews the current status and trends related to the nature, health and productivity of Alberta’s life sciences industry.